Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study

Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study

Abstract Background Our aim was to investigate dynamic changes in hepatitis B virus (HBV) surface antibody (HBsAb) titer and the associated risk of HBV reactivation and clinical course in patients with HBV surface antigen negative/core antibody positive (HBsAg−/HBcAb+) serostatus during antirheumati...

Full description

Bibliographic Details
Main Authors: Ya-Chih Tien, Hsu-Heng Yen, Ching-Fang Li, Mei-Ping Liu, Yin-Tzu Hsue, Ming-Hui Hung, Ying-Ming Chiu
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Arthritis Research & Therapy
Subjects:
DMARDs (biologic)
Hepatitis B virus surface/core antibody (HBsAb/HBcAb)
Rheumatic diseases
HBV reactivation
Online Access:http://link.springer.com/article/10.1186/s13075-018-1748-z

Internet

http://link.springer.com/article/10.1186/s13075-018-1748-z

Similar Items